Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.

Medicine - 1 Nov 2016

Han Eugene, Park Hye Sun, Kwon Obin, Choe Eun Yeong, Wang Hye Jin, Lee Yong-Ho, Lee Sang-Hak, Kim Chul Hoon, Kim Lee-Kyung, Kwak Soo Heon, Park Kyong Soo, Kim Chul Sik, Kang Eun Seok

Abstract excerpt

Incretin hormone-based therapy in type 2 diabetes has been widely used, and dipepdityl peptidase-4 (DPP-4) inhibitors, which prevent incretin degradation, have become popular oral hypoglycemic agents. The efficacy of DPP-4 inhibitors varies from individuals, and factors determining responses to DPP-4 inhibitors have not been fully established. We aimed to investigate whether genetic variations in glucagon-like...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 2
Share to Diabetes Treatment and Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Glucagon-Like Peptide-1 Receptor

Share to Metabolism, Diabetes, and Cancer

Share to Pancreatic function and diabetes

Source

Open in PubMed Open full text

Identifiers

PMID: 27858848
DOI: 10.1097/MD.0000000000005155
PMCID: PMC5591096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.PMID 27858848Read ↗

Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors.Semantic proximity Read ↗

GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 DiabetesSemantic proximity Read ↗

Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes.Semantic proximity Read ↗

Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort studySemantic proximity Read ↗

Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.Semantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity Read ↗

Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus.Semantic proximity Read ↗

GLP1R Rs3765467 Polymorphism Is Associated With The Risk Of Early-Onset Type 2 DiabetesSemantic proximity Read ↗

Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.Semantic proximity Read ↗

Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes.Semantic proximity Read ↗

GLP1R (glucagon-like-peptide-1 incretin receptor), diabetes and obesity phenotypes: An in silico approach revealed new pathogenic variants.Semantic proximity Read ↗

A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.